Key Details
Price
$124.54Annual Revenue
$3.83 BAnnual EPS
$6.10Annual ROE
12.16%Beta
0.41Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
After the 3Q24 report and the FDA's approval of zanidatamab, Jazz Pharmaceuticals' stock rose significantly, even with some difficulties in its narcolepsy products due to Avadel's Lumryz. While sales of Xyrem are decreasing, Jazz is experiencing growth with Xywav and Epidiolex in its neuroscience division. The oncology sector is expanding thanks to the approval of zanidatamab and other important medications like Rylaze and Zepzelca, which are essential for reaching their Vision 2025 sales targets.
Bruce Cozadd, the Co-Founder, Chairperson, and CEO of Jazz Pharmaceuticals, plans to step down as CEO once a successor is appointed, which is anticipated to happen by the end of 2025. He will remain as Chair of the Board after his retirement. The Board will conduct a thorough search for the new CEO, aiming to complete the process in 2025.
Nine abstracts will be presented, including initial findings from the EpiCom Trial, which looks at behavioral outcomes in patients with tuberous sclerosis complex and indicates improvements in behavioral symptoms. Additionally, real-world data from the BECOME surveys, which gather information from long-term care facility nurses and caregivers, will also be shared. Jazz Pharmaceuticals is showcasing these findings at the American Epilepsy Society 2024 Annual Meeting in Los Angeles from December 6-10.
DUBLIN, Dec. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced that it will hold a webcast on Wednesday, December 11, 2024, at 4:30 p.m. ET / 9:30 p.m. GMT.
The average price target suggests that Jazz (JAZZ) could increase by 44.4%. Although studies indicate that this measure is not very reliable, an increase in earnings estimate revisions might indicate that the stock could rise soon.
After receiving approval from the FDA, Jazz's Ziihera is now the first bispecific antibody that targets two HER2 proteins and is a chemotherapy-free option for treating biliary tract cancer.
On Wednesday, Jazz Pharmaceuticals announced that the U.S. Food and Drug Administration has approved their medication, zanidatamab-hrii, for treating a specific kind of biliary tract cancer.
At Zacks, we concentrate on the reliable Zacks Rank system, which highlights earnings estimates and changes in those estimates to identify excellent stocks. However, we also keep an eye on the most recent trends in value, growth, and momentum to support our top selections.
Investors should closely monitor Jazz (JAZZ) stock due to recent changes in the options market.
Jazz (JAZZ) has received a Zacks Rank #2 (Buy) upgrade, indicating increased confidence in the company's potential earnings. This could lead to a rise in the stock price soon.
FAQ
- What is the primary business of Jazz Pharmaceuticals?
- What is the ticker symbol for Jazz Pharmaceuticals?
- Does Jazz Pharmaceuticals pay dividends?
- What sector is Jazz Pharmaceuticals in?
- What industry is Jazz Pharmaceuticals in?
- What country is Jazz Pharmaceuticals based in?
- When did Jazz Pharmaceuticals go public?
- Is Jazz Pharmaceuticals in the S&P 500?
- Is Jazz Pharmaceuticals in the NASDAQ 100?
- Is Jazz Pharmaceuticals in the Dow Jones?
- When was Jazz Pharmaceuticals's last earnings report?
- When does Jazz Pharmaceuticals report earnings?
- Should I buy Jazz Pharmaceuticals stock now?